Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders
New England Journal of Medicine · 03.09.2026 · 395 (9) · 926-929
DOI: 10.1056/nejmc2603114 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 03.09.2026. Verfasst von Yu-Hang Cheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups.
Autor:innen und Institutionen
- Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China.
- Shenzhen Genocury Biotech, Shenzhen, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cheng, Y. H., Shang, K., Qin, C., Dong, M. H., Chu, Y. H., Huang, K., Mei, Z. C., Xiao, J., Liang, Z. H., Li, Y. H., Wang, W., & Tian, D. S. (2026). Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders. New England Journal of Medicine, 395(9), 926-929. https://doi.org/10.1056/nejmc2603114
Vancouver
Cheng YH, Shang K, Qin C, Dong MH, Chu YH, Huang K, et al. Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders. New England Journal of Medicine. 2026;395(9):926-929. doi:10.1056/nejmc2603114
BibTeX
@article{Cheng2026,
author = {Cheng, Yu-Hang and Shang, Ke and Qin, Chuan and Dong, Ming-Hao and Chu, Yun-Hui and Huang, Ke and Mei, Zhi-Cheng and Xiao, Jun and Liang, Zi-Hao and Li, Yu-Hang and Wang, Wei and Tian, Dai-Shi},
title = {Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {9},
pages = {926--929},
doi = {10.1056/nejmc2603114}
}
EUVIMED